Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (nash) in five european countries in 2018: A cost-of-illness analysis

Jörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, Lawrence Serfaty, Alessio Aghemo, Salvador Augustin, Emmanuel Tsochatzis, Victor de Ledinghen, Elisabetta Bugianesi, Manuel Romero-Gomez, Heike Bantel, Stephen D Ryder, Jerome Boursier, Vincent Leroy, Javier Crespo, Laurent Castera, Lefteris Floros, Vincenzo Atella, Jorge Mestre-Ferrandiz, Rachel ElliottAchim Kautz, Alice Morgan, Sally Hartmanis, Sharad Vasudevan, Lynne Pezzullo, Aldo Trylesinski, Sandrine Cure, Victoria Higgins, Vlad Ratziu

Research output: Contribution to journalArticlepeer-review

115 Downloads (Pure)


BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom (UK) in 2018.

METHODS: The socioeconomic burden of diagnosed NASH was estimated using cost-of-illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed patients do not incur costs in the study, the probability of diagnosis is central to cost estimation. The analysis was based on literature review, databases and consultation with clinical experts, economists and patient groups.

RESULTS: The proportion of adult NASH patients with a diagnosis ranged from 11.9% to 12.7% across countries, which increased to 38.8% to 39.1% for advanced fibrosis (F3 to F4 compensated cirrhosis). Total economic costs were €8,548-19,546M. Of these, health system costs were €619-1,292M. Total wellbeing costs were €41,536-90,379M. The majority of the undiagnosed population (87.3% to 88.2% of total prevalence) was found to have early stage NASH which, left untreated, may progress to more resource consuming ESLD over time.

CONCLUSIONS: This study found the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs.


Dive into the research topics of 'Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (nash) in five european countries in 2018: A cost-of-illness analysis'. Together they form a unique fingerprint.

Cite this